ABOS
Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc
$ABOS reports Acumen Pharma's $193M cash balance and ACU193 drug update.
Acumen Pharmaceuticals releases 2022 financial results, shows cash balance of $193.4m as of Dec. 31, 2022, and provides a business update, including ACU193, a drug for treating Alzheimer's disease. Phase 1 topline results are expected to report in Q3 2023, while FDA interaction may happen in Q4 2023. ACU193 was granted Fast Track designation in Oct. 2022. The company also expanded its team, appointing Liean Schenck as VP of Chemistry and Manufacturing and Derek Meisner as Chief Legal Officer. Despite reporting a net loss of $42.1m for 2021, the company is optimistic about ACU193.
2d ago
$ABOS